JPRN-UMIN000010935已完成未知
The combination therapy of pemetrexed and continued EGFR-TKIs beyond disease progression to first-line EGFR-TKIs treatments in elderly patients with advanced non-small-cell lung cancer harboring EGFR mutations: a phase 2 trial. - Pemetrexed and continued EGFR-TKIs beyond progressive disease in elderly patients with EGFR-mutant advanced NSCLC.
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine0 个研究点目标入组 22 人开始时间: 2013年6月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria are as follows 1: Symptomatic brain metastasis. 2: History of radiotherapy to primary lesion. 3: Severe and unstable medical comorbidities. 4: Difficulty in ingestion. 5: With third-space fluid to be drained. 6: Pregnant or breastfeeding women. Willing to get pregnant. 7: Contraindication for taking EGFR-TKIs. 8: Active double cancers. 9: History of severe allergy to drugs. 10: Judgment to attending physician.
研究者
相似试验
招募中
2 期
Phase II study of Combination Therapy of Pemetrexed/Carboplatin/Bevacizumab for Advanced Non-small-cell lung cancernon-squamous non-small-cell lung cancerJPRN-UMIN000004685ational Hospital Organization Hokkaido Medical Center38
招募中
2 期
Phase II Study of Pemetrexed in Combination with Carboplatin Followed by Pemetrexed Maintenance Therapy for Elderly Advanced Non-squamous and Non-small Cell Lung Cancer.on-squamous non-small-cell lung cancerJPRN-UMIN000006139Tochigi Thoracic Oncology Research Organization50
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEstudio en fase II de pemetrexed en combinación con cisplatino y cetuximab en el carcinoma de células escamosas de cabeza y cuello recurrente o metastásicoRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCarcinoma de células escamosas de cabeza y cuello recurrente o metastásicoMedDRA version: 12.0Level: LLTClassification code 10063569Term: Metastatic squamous cell carcinomaEUCTR2009-011611-21-ESEli Lilly and Company Ltd.65
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEUCTR2009-011611-21-DEEli Lilly and Company Ltd.65
进行中（未招募）
1 期
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEUCTR2009-011611-21-GBEli Lilly and Company Ltd.65